Postpartum prescription of GLP-1RAs in Denmark increased between 2018 and 2024, with semaglutide accounting for most prescriptions since 2023.

Most users had overweight or obesity, and only 23% had a diabetes diagnosis, suggesting weight reduction as the main reason for use.

This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.